Investing in healthtech, interview w. Baudouin Hue (Karista VC) 🏥

Key insights:* Interview with Baudouin Hue, Partner at Karista.vc* Healthtech is often disregarded as an impact topic as most healthtech funds don’t take impact into account in their assessments. Karista and Baudouin prove that healthtech can be an impact topic* Karista splits up solutions in healthtech into 4 buckets: 1. Software in healthcare, 2. Outsourced R&D solutions, 3. Patient data for personalized care, and 4. Augmented medical devices* Karista prefers solutions that sell B2G and that can be reimbursed (by the state in Europe and insurance, primarily in the USA) - one of the angles to impact in healthcare is ensuring that most people have access to better treatments* Prices of medicine are 2x-10x higher in the US than in Europe - that’s why most healthtech move to the US as soon as they have succeeded in one or a couple of markets in EuropeThemes discussed:* Is health an impact topic? 🏥* Are all healthtech VCs impact VCs? 🤔* Differentiating healthtech and biotech 🧬* Key solution areas in healthtech 💡* A geographical view of healthtech 🗺️* Healthtech in development economies 🌏* B2G vs B2C vs B2B 💼* Creating an A- and B-team in healthcare 🥇* Being an impact generalist VC in healthtech 🔍* Major trends in healthtech - Karista builds a growth fund 📈 This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit impactvc.substack.com